Showing 61 - 80 results of 21,682 for search '(( significant case based ) OR ( significant greater decrease ))', query time: 0.78s Refine Results
  1. 61

    The base case analysis. by Wenwang Lang (20293527)

    Published 2025
    “…</p><p>Results</p><p>In the base-case scenario, adding benmelstobart and anlotinib to chemotherapy increased QALYs by 0.34 at an additional cost of $24,684.07, yielding an ICER of $71,559.84 per QALY. …”
  2. 62
  3. 63

    Base-case results. by Shuo Kang (1306860)

    Published 2025
    “…One-way and probabilistic sensitivity analyses were conducted to estimate the robustness of the model results,</p><p>Results</p><p>In base-case analysis, compared with toripalimab plus chemotherapy and chemotherapy alone, ITH-testing directed therapy could bring additional 0.14 QALYs and 0.29 QALYs, with marginal costs of $3750.75 and $7778.18, resulting in the ICER of $27,353.27/QALY and $26,461.46/QALY, respectively, which lower than the Chinese willingness-to-pay (WTP) threshold. …”
  4. 64
  5. 65
  6. 66

    Base-case results. by Mingxi Xie (19812594)

    Published 2024
    “…The model time-frame was one-year. Base-case analysis and sensitivity analysis were performed. …”
  7. 67

    Base-case analysis. by Akiko Kowada (14659965)

    Published 2023
    “…The willingness-to-pay (WTP) threshold was set at US$50,000 per QALY gained. In the base-case analysis, HTLV-1 antenatal screening (US$76.85, 24.94766 QALYs, 24.94813 LYs, ICER; US$40,100 per QALY gained) was cost-effective compared with no screening (US$2.18, 24.94580 QALYs, 24.94807 LYs). …”
  8. 68
  9. 69
  10. 70
  11. 71
  12. 72
  13. 73
  14. 74
  15. 75
  16. 76
  17. 77
  18. 78
  19. 79
  20. 80